Literature DB >> 19398869

Factors determining cardiovascular and renal outcomes after adrenalectomy in patients with aldosterone-producing adrenal adenoma.

Terry Ting-Yu Chiou1, Po-Hui Chiang, Morgan Fuh, Rue-Tsuan Liu, Wei-Ching Lee, Wen-Chin Lee, Hwee-Yeong Ng, Yu-Che Tsai, Fong-Rong Chuang, Chao-Cheng Huang, Chien-Te Lee.   

Abstract

Primary aldosteronism is an important cause of secondary hypertension, because it is potentially curable, especially in case of unilateral aldosterone-producing adrenal adenoma (APA). However, the information is limited concerning the cardiovascular and renal outcomes in this patient population. We studied 52 patients with APA in order to determine the pre-operative and post-operative factors predicting cardiovascular and renal outcomes. All 52 patients were hypertensive before the operation. Among 35 patients who underwent pre-operative electrocardiogram, 23 patients had left ventricular hypertrophy (LVH). Patients with LVH had lower estimated glomerular filtration rate (eGFR). Adrenalectomy successfully normalized or improved hypertension, hypokalemia, and aldosterone excess. One month after the adrenalectomy, 32 patients (62%) became normotensive, but 20 patients (38%) remained hypertensive. However, after an average follow-up period of 51 months, only 18 patients remained normotensive, while 34 patients were hypertensive. Thus, the rate of recurrent hypertension after adrenalectomy was high (14/32, 43%). Pre-operative systolic blood pressure (BP), diastolic BP, and post-operative plasma aldosterone concentrations were the only variables significantly different between the hypertensive and normotensive patients. Using pre-operative BP 165/110 mmHg as a cutoff has good positive predictive values (73-92%) for post-operative long-term hypertension. Patients whose renal function worsened after adrenalectomy had significantly higher pre-operative plasma active renin levels. Thus, in patients with APA, the presence of LVH is correlated with impaired renal function (lower eGFR). In conclusion, pre-operative BP and post-operative plasma aldosterone are important in predicting post-adrenalectomy hypertension, and a lower pre-operative plasma renin predicts the improvement in renal function after adrenalectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398869     DOI: 10.1620/tjem.218.17

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

Review 1.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

2.  Risk of New-Onset Dyslipidemia After Laparoscopic Adrenalectomy in Patients with Primary Aldosteronism.

Authors:  Mayuko Kaga; Takanobu Utsumi; Tomoaki Tanaka; Takashi Kono; Hidekazu Nagano; Koji Kawamura; Naoto Kamiya; Takashi Imamoto; Naoki Nihei; Yukio Naya; Hiroyoshi Suzuki; Tomohiko Ichikawa
Journal:  World J Surg       Date:  2015-12       Impact factor: 3.352

3.  Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.

Authors:  Yongji Yan; Chao Wang; Yiqin Lu; Huijie Gong; Zhun Wu; Xin Ma; Hongzhao Li; Baojun Wang; Xu Zhang
Journal:  J Physiol Biochem       Date:  2017-11-21       Impact factor: 4.158

4.  Editorial comment from Dr Nishikawa et al. to preoperative masked renal damage in japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.

Authors:  Tetsuo Nishikawa; Masao Omura; Jun Saito; Yoko Matsuzawa; Tomoshige Kino
Journal:  Int J Urol       Date:  2012-12-11       Impact factor: 3.369

Review 5.  Hypertension outcomes of adrenalectomy in patients with primary aldosteronism: a systematic review and meta-analysis.

Authors:  Yu Zhou; Meilian Zhang; Sujie Ke; Libin Liu
Journal:  BMC Endocr Disord       Date:  2017-10-03       Impact factor: 2.763

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.